238 related articles for article (PubMed ID: 22986534)
1. Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression.
Hu Q; Lu YY; Noh H; Hong S; Dong Z; Ding HF; Su SB; Huang S
Oncogene; 2013 Aug; 32(34):3933-43. PubMed ID: 22986534
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
3. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
4. GATA6 promotes colon cancer cell invasion by regulating urokinase plasminogen activator gene expression.
Belaguli NS; Aftab M; Rigi M; Zhang M; Albo D; Berger DH
Neoplasia; 2010 Nov; 12(11):856-65. PubMed ID: 21076612
[TBL] [Abstract][Full Text] [Related]
5. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
6. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells.
Subramanian R; Gondi CS; Lakka SS; Jutla A; Rao JS
Int J Oncol; 2006 Apr; 28(4):831-9. PubMed ID: 16525631
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Li XF; Yan PJ; Shao ZM
Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
[TBL] [Abstract][Full Text] [Related]
8. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice.
Gondi CS; Lakka SS; Dinh DH; Olivero WC; Gujrati M; Rao JS
Clin Cancer Res; 2007 Jul; 13(14):4051-60. PubMed ID: 17634529
[TBL] [Abstract][Full Text] [Related]
10. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
11. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Mori Y; Akita K; Tanida S; Ishida A; Toda M; Inoue M; Yashiro M; Sawada T; Hirakawa K; Nakada H
J Biol Chem; 2014 Dec; 289(51):35193-204. PubMed ID: 25371209
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
13. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
15. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Guo Y; Pakneshan P; Gladu J; Slack A; Szyf M; Rabbani SA
J Biol Chem; 2002 Nov; 277(44):41571-9. PubMed ID: 12198113
[TBL] [Abstract][Full Text] [Related]
16. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1.
Sánchez-Tilló E; de Barrios O; Siles L; Amendola PG; Darling DS; Cuatrecasas M; Castells A; Postigo A
Clin Cancer Res; 2013 Mar; 19(5):1071-82. PubMed ID: 23340304
[TBL] [Abstract][Full Text] [Related]
17. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.
Pakneshan P; Szyf M; Farias-Eisner R; Rabbani SA
J Biol Chem; 2004 Jul; 279(30):31735-44. PubMed ID: 15150277
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.
Au Yeung CL; Tsang TY; Yau PL; Kwok TT
Oncogene; 2011 May; 30(21):2401-10. PubMed ID: 21242962
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.
Amos S; Redpath GT; Dipierro CG; Carpenter JE; Hussaini IM
J Neuropathol Exp Neurol; 2010 Jun; 69(6):582-92. PubMed ID: 20467333
[TBL] [Abstract][Full Text] [Related]
20. Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma.
Rao Gogineni V; Kumar Nalla A; Gupta R; Gorantla B; Gujrati M; Dinh DH; Rao JS
Int J Oncol; 2010 Apr; 36(4):809-16. PubMed ID: 20198323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
